Paolo Milani works as a consultant in the Pavia Amyloidosis Research and Treatment Center at the Foundation “IRCCS Policlinico San Matteo”, Pavia, Italy. This is the national referral center for patients with amyloidosis in Italy, seeing over 200 newly-diagnosed patients with systemic AL amyloidosis every year. He is a member at large of the Board of Directors of the International Society of Amyloidosis.
Dr Milani currently works on all of the ongoing clinical trials at the Pavia Center and is the Principal Investigator of a clinical trial about the use of pomalidomide and daratumumab in relapsed/refractory patients with AL amyloidosis that is due to start. In addition, an important part of his research is the introduction and validation of surrogate endpoints (biomarkers-based) that could speed up enrolment and study termination, possibly also in drug registration trials. He is also involved in several laboratory projects with a specific focus on the application of mass spectrometry in the evaluation of monoclonal proteins.
EM-60280 - Date of preparation: April 2021